{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:22:52Z","timestamp":1780550572327,"version":"3.54.1"},"reference-count":69,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014481","name":"Kite Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014481","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.omtm.2024.101212","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T17:16:08Z","timestamp":1707844568000},"page":"101212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Optimization of anti-CD19 CAR T\u00a0cell production for treatment of patients with chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"32","author":[{"given":"Christina","family":"Amatya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Weissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki","family":"Fellowes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norris","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren C.","family":"Cutmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle A.","family":"Natrakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven L.","family":"Highfill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4362-9875","authenticated-orcid":false,"given":"James N.","family":"Kochenderfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2024.101212_bib2","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/s41571-019-0239-8","article-title":"Chronic lymphocytic leukaemia: from genetics to treatment","volume":"16","author":"Bosch","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omtm.2024.101212_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omtm.2024.101212_bib4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-021-01054-w","article-title":"Current and future treatment strategies in chronic lymphocytic leukemia","volume":"14","author":"Patel","year":"2021","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.omtm.2024.101212_bib5","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s12325-011-0032-2","article-title":"Rituximab in chronic lymphocytic leukemia","volume":"28","author":"James","year":"2011","journal-title":"Adv. Ther."},{"key":"10.1016\/j.omtm.2024.101212_bib6","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","article-title":"Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity","volume":"19","author":"Byrd","year":"2001","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omtm.2024.101212_bib7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/j.seminhematol.2023.01.002","article-title":"Challenges and opportunities of CAR T-cell therapies for CLL","volume":"60","author":"Zhao","year":"2023","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.omtm.2024.101212_bib8","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.hoc.2021.03.011","article-title":"Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and Beyond","volume":"35","author":"Shadman","year":"2021","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"10.1016\/j.omtm.2024.101212_bib9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","article-title":"CAR T\u00a0cell therapies for patients with multiple myeloma","volume":"18","author":"Mikkilineni","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omtm.2024.101212_bib10","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omtm.2024.101212_bib11","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s43018-021-00241-5","article-title":"Engineering-enhanced CAR T\u00a0cells for improved cancer therapy","volume":"2","author":"Milone","year":"2021","journal-title":"Nat. Can. (Ott.)"},{"key":"10.1016\/j.omtm.2024.101212_bib12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","article-title":"Chimeric antigen receptor T-cell therapies for lymphoma","volume":"15","author":"Brudno","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omtm.2024.101212_bib13","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2024.101212_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omtm.2024.101212_bib15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2024.101212_bib16","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2024.101212_bib17","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","article-title":"Safety and feasibility of anti-CD19 CAR T\u00a0cells with fully human binding domains in patients with B-cell lymphoma","volume":"26","author":"Brudno","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2024.101212_bib18","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omtm.2024.101212_bib19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1046\/j.1468-0734.2000.00002.x","article-title":"Morphological and immunophenotypic features of chronic lymphocytic leukemia","volume":"4","author":"Matutes","year":"2000","journal-title":"Rev. Clin. Exp. Hematol."},{"key":"10.1016\/j.omtm.2024.101212_bib20","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T\u00a0cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omtm.2024.101212_bib21","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T\u00a0cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2024.101212_bib22","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2024.101212_bib23","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T\u00a0cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2024.101212_bib24","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-Specific chimeric antigen Receptor-modified T\u00a0cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omtm.2024.101212_bib25","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T\u00a0cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2024.101212_bib26","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1200\/JCO.19.03237","article-title":"Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omtm.2024.101212_bib27","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1\u20132 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2024.101212_bib28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2024.101212_bib29","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2024.101212_bib30","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLLpatients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2024.101212_bib31","first-page":"2427","article-title":"Chronic lymphocytic leukemia T\u00a0cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2024.101212_bib32","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T\u00a0cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2024.101212_bib33","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omtm.2024.101212_bib34","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in\u00a0vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2024.101212_bib35","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s13238-019-0643-y","article-title":"Chimeric antigen receptor T (CAR-T) cells expanded with IL-7\/IL-15 mediate superior antitumor effects","volume":"10","author":"Zhou","year":"2019","journal-title":"Protein Cell"},{"key":"10.1016\/j.omtm.2024.101212_bib36","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","article-title":"Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains","volume":"25","author":"Alabanza","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101212_bib37","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1080\/10428194.2022.2076853","article-title":"Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience","volume":"63","author":"Seitter","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.omtm.2024.101212_bib38","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1089\/hum.2005.16.457","article-title":"Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions","volume":"16","author":"Hughes","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2024.101212_bib39","doi-asserted-by":"crossref","first-page":"a037929","DOI":"10.1101\/cshperspect.a037929","article-title":"Memory t-cell heterogeneity and terminology","volume":"13","author":"Muroyama","year":"2021","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.omtm.2024.101212_bib40","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/44385","article-title":"Two subsets of memory T lymphocytes with distinct homing potentials and effector functions","volume":"401","author":"Sallusto","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2024.101212_bib41","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2024.101212_bib42","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T\u00a0cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2024.101212_bib43","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jcyt.2013.06.003","article-title":"Simplified process for the production of anti-CD19-CAR-engineered T\u00a0cells","volume":"15","author":"Tumaini","year":"2013","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omtm.2024.101212_bib44","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","article-title":"CAR T\u00a0cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial","volume":"27","author":"Cordoba","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2024.101212_bib45","series-title":"Transact","year":"2023"},{"key":"10.1016\/j.omtm.2024.101212_bib46","series-title":"Cloudz Human T Cell Activation Kit","year":"2020"},{"key":"10.1016\/j.omtm.2024.101212_bib47","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: Establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2024.101212_bib48","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/CJI.0000000000000193","article-title":"CD19 Chimeric Antigen Receptor T Cells from Patients with Chronic Lymphocytic Leukemia Display an Elevated IFN-\u03b3 Production Profile","volume":"41","author":"Magalhaes","year":"2018","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.omtm.2024.101212_bib49","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/mt.2016.63","article-title":"GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected from Activation-induced Cell Death by PD-1 Blockade","volume":"24","author":"Gargett","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101212_bib50","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.semcancer.2019.11.004","article-title":"Determinants of response and resistance to CAR T\u00a0cell therapy","volume":"65","author":"Lesch","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.omtm.2024.101212_bib51","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.omtm.2021.02.002","article-title":"Enriching leukapheresis improves T\u00a0cell activation and transduction efficiency during CAR T processing","volume":"20","author":"Noaks","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2024.101212_bib52","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.3389\/fimmu.2020.01217","article-title":"Next-Generation Manufacturing Protocols Enriching T(SCM) CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients","volume":"11","author":"Arcangeli","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2024.101212_bib53","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omtm.2024.101212_bib54","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti\u2013B-Cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omtm.2024.101212_bib55","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","article-title":"Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial","volume":"29","author":"Lin","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2024.101212_bib56","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nri1842","article-title":"Adoptive immunotherapy for cancer: Building on success","volume":"6","author":"Gattinoni","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omtm.2024.101212_bib57","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1172\/JCI24480","article-title":"Acquisition of full effector function in\u00a0vitro paradoxically impairs the in\u00a0vivo antitumor efficacy of adoptively transferred CD8+ T\u00a0cells","volume":"115","author":"Gattinoni","year":"2005","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2024.101212_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.745109","article-title":"A Correlation Between Differentiation Phenotypes of Infused T Cells and Anti-Cancer Immunotherapy","volume":"12","author":"Ren","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2024.101212_bib59","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T\u00a0cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2024.101212_bib60","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.omtm.2024.101212_bib61","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2141.2010.08297.x","article-title":"Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma","volume":"151","author":"Mihara","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omtm.2024.101212_bib62","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1182\/blood-2009-08-232967","article-title":"Antibody-mediated B-cell depletion before adoptive immunotherapy with T\u00a0cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice","volume":"114","author":"James","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2024.101212_bib63","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T\u00a0cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2024.101212_bib64","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/CJI.0b013e3181ac6138","article-title":"Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor","volume":"32","author":"Kochenderfer","year":"2009","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.omtm.2024.101212_bib65","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.omto.2023.07.001","article-title":"Development of a bicistronic anti-CD19\/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletions","volume":"30","author":"Lam","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omtm.2024.101212_bib66","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jim.2003.10.017","article-title":"The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in\u00a0vitro and in\u00a0vivo","volume":"285","author":"Hermans","year":"2004","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.omtm.2024.101212_bib67","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.ymthe.2020.10.008","article-title":"Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7","volume":"29","author":"Amatya","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101212_bib68","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/s41467-020-15145-8","article-title":"Author Correction: Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains","volume":"11","author":"Lam","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2024.101212_bib69","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2024.101212_bib70","series-title":"Guidance for Industry: cGMP for Phase I Investigational Drugs","year":"2008"}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050124000287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050124000287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T17:14:43Z","timestamp":1722100483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050124000287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2329050124000287"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2024.101212","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimization of anti-CD19 CAR T\u00a0cell production for treatment of patients with chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2024.101212","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"101212"}}